Ipratropium or Salbutamol Sulphate Alone or Combination Therapy Salbutamol and Ipratropium in Patients With COPD

Pulmonary Disease, Chronic Obstructive Clinical Trial

Official title:

A Randomised, Double-blind, Active-controlled, Within-patient Trial Comparing the Effect of Single Doses of Nebulised Ipratropium 500µg, Salbutamol Sulphate 3mg, Salbutamol 6mg and the Combination Therapy Salbutamol Sulphate 3 mg Plus Ipratropium 500µg on Arterial Oxygen Saturation in Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02182856
• Other study ID #: 1012.39
• Status: Completed
• Phase: Phase 4
• First received: July 4, 2014
• Last updated: July 4, 2014
• Start date: February 1998

Study information

• Verified date: July 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

Study to compare the effects of nebulised salbutamol or ipratropium alone in patients with COPD with those of combined salbutamol and ipratropium nebuliser solution on arterial oxygen saturation (SaO2) and to characterise patients with COPD (chronic obstructive pulmonary disease) at risk of significant arterial oxygen desaturation following nebulised salbutamol.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. primary completion date: July 2000
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Male and female patients with moderate to severe stable COPD:

• Patients with a diagnosis of chronic bronchitis and/or emphysema

• FEV1 <65% of predicted value without regard to prior treatment

• Forced expiratory ration (FER = FEV1/VC) <70% of predicted value without regard to prior treatment

• Patients must not have had a respiratory infection or an exacerbation of COPD during the four weeks immediately prior to entering the trial

• Patients must not have changed their normal treatment for COPD during the four weeks immediately prior to entering the trial

• Patient aged =40 years

• Patients with a smoking history of =15 pack-years

• Patients must have given informed consent to participate in the trial

Exclusion Criteria:

• Patients with a diagnosis of asthma, bronchiectasis, cystic fibrosis or bronchiolitis obliterans

• Patients with any of the following:

• untreated angle closure glaucoma

• hypertrophic obstructive cardiomyopathy

• tachyarrhythmia

• recent myocardial infarction (within six months of screening visit)

• severe organic cardiac or vascular disorder

• untreated hyperthyroidism

• diabetes mellitus (after approval of Protocol Amendment 1, the inclusion of well controlled diabetic patients was allowed)

• Patients who are pregnant, or who are planning a pregnancy, and nursing mothers

• Patients known to be hypersensitive to anticholinergic drugs or to ß2 agonists

• Patients known to abuse drugs or alcohol

• Patients, who in the opinion of the investigator, are likely not to co-operate with any of the requirements of the trial

• Patients with a PaO2 (arterial carbon dioxide tension) <56 mmHg (7.5 kPa) at rest while breathing air without regard to prior treatment

• Patients with a SaO2 =85% at rest while breathing air without regard to prior treatment

• Patients who are taking part in another investigation, and patients who have participated in another clinical trial during the three months immediately preceding entry to this trial

• Patients on home oxygen concentrator therapy

• Patients who have previously participated in the randomised phase of this trial

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Disease
• Lung Diseases
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Ipratropium bromide 500 µg/salbutamol sulphate 3 mg

• Ipratropium 500 µg

• Salbutamol sulphate 3 mg

• Salbutamol sulphate 6 mg

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the curve of arterial oxygen saturation (SaO2)		over 70 min observation period from each start of nebulisation	No
Secondary	Forced expiratory volume in the first second of expiration (FEV1)		up to 60 min after end of nebulisation	No
Secondary	Relaxed (expiratory) vital capacity (VC)		up to 60 min after end of nebulisation	No
Secondary	Forced (expiratory) vital capacity (FVC)		up to 60 min after end of nebulisation	No
Secondary	Forced expiratory ratio (FER)		up to 60 min after end of nebulisation	No

External Links

•   Link